Ahmed Mohammed Hager A, Yang Ju Dong, Giama Nasra H, Choi Jonggi, Ali Hawa M, Mara Kristin C, Harmsen William S, Wiesner Russell H, Leise Michael D, Therneau Terry M, Roberts Lewis R
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minn., USA.
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn., USA.
Liver Cancer. 2017 Feb;6(2):126-136. doi: 10.1159/000450833. Epub 2016 Dec 17.
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide, and a rising cause of cancer mortality in the U.S. Liver cirrhosis is the major risk factor for HCC. Surveillance of persons with cirrhosis facilitates early detection and improves outcomes. We assessed the surveillance rate for HCC within a major academic health system and identified factors influencing surveillance.
We examined the surveillance rate for HCC using liver ultrasound, CT, or MRI, and factors influencing surveillance in a cohort of 369 Minnesota residents with cirrhosis seen at the Mayo Clinic between 2007 and 2009.
Ninety-three percent of cirrhosis patients received at least one surveillance study, but only 14% received the recommended uninterrupted semiannual surveillance. Thirty percent received ≥75% of recommended surveillance, and 59% received ≥50% of recommended surveillance. Factors increasing surveillance included gastroenterology or hepatology specialist visits (p < 0.0001), advanced liver disease as assessed by hepatic encephalopathy (p = 0.0008), and comorbid illness as assessed by diabetes mellitus (p = 0.02). Age, sex, race, residence, cirrhosis etiology, or number of primary care visits did not significantly affect the rate of surveillance.
While the rate of surveillance in a major academic health system was higher than reported in other studies, surveillance was heavily dependent on visits to a subspecialist. This suggests a major and urgent national need to improve identification of individuals at risk for HCC in the primary care setting and the initiation and maintenance of surveillance by primary care practitioners.
肝细胞癌(HCC)是全球癌症相关死亡的第二大常见原因,且在美国癌症死亡率呈上升趋势。肝硬化是HCC的主要危险因素。对肝硬化患者进行监测有助于早期发现并改善预后。我们评估了一个大型学术医疗系统内HCC的监测率,并确定了影响监测的因素。
我们在2007年至2009年间于梅奥诊所就诊的369名明尼苏达州肝硬化患者队列中,研究了使用肝脏超声、CT或MRI进行HCC监测的比率以及影响监测的因素。
93%的肝硬化患者接受了至少一项监测研究,但只有14%的患者接受了推荐的不间断半年一次的监测。30%的患者接受了≥75%的推荐监测,59%的患者接受了≥50%的推荐监测。增加监测的因素包括胃肠病学或肝病学专科就诊(p<0.0001)、根据肝性脑病评估的晚期肝病(p = 0.0008)以及根据糖尿病评估的合并症(p = 0.02)。年龄、性别、种族、居住地、肝硬化病因或初级保健就诊次数对监测率没有显著影响。
虽然一个大型学术医疗系统的监测率高于其他研究报告的水平,但监测严重依赖于专科医生就诊。这表明国家迫切需要大力改进在初级保健环境中对HCC高危个体的识别,以及由初级保健医生启动和维持监测。